Cargando…
A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling
The current anti-cancer treatments are not enough to eradicate tumors, and therefore, new modalities and strategies are still needed. Most tumors generate an inflammatory tumor microenvironment (TME) and maintain the niche for their development. Because of the critical role of inflammation via high-...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998738/ https://www.ncbi.nlm.nih.gov/pubmed/35408786 http://dx.doi.org/10.3390/ijms23073426 |
_version_ | 1784685015155605504 |
---|---|
author | Tanuma, Sei-ichi Oyama, Takahiro Okazawa, Miwa Yamazaki, Hiroaki Takao, Koichi Sugita, Yoshiaki Amano, Shigeru Abe, Takehiko Sakagami, Hiroshi |
author_facet | Tanuma, Sei-ichi Oyama, Takahiro Okazawa, Miwa Yamazaki, Hiroaki Takao, Koichi Sugita, Yoshiaki Amano, Shigeru Abe, Takehiko Sakagami, Hiroshi |
author_sort | Tanuma, Sei-ichi |
collection | PubMed |
description | The current anti-cancer treatments are not enough to eradicate tumors, and therefore, new modalities and strategies are still needed. Most tumors generate an inflammatory tumor microenvironment (TME) and maintain the niche for their development. Because of the critical role of inflammation via high-mobility group box 1 (HMGB1)–receptor for advanced glycation end-products (RAGE) signaling pathway in the TME, a novel compound possessing both anti-cancer and anti-inflammatory activities by suppressing the HMGB1-RAGE axis provides an effective strategy for cancer treatment. A recent work of our group found that some anti-cancer 3-styrylchromones have weak anti-inflammatory activities via the suppression of this axis. In this direction, we searched such anti-cancer molecules possessing potent anti-inflammatory activities and discovered 7-methoxy-3-hydroxy-styrylchromone (C6) having dual suppressive activities. Mechanism-of-action studies revealed that C6 inhibited the increased phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) under the stimulation of HMGB1-RAGE signaling and thereby suppressed cytokine production in macrophage-like RAW264.7 cells. On the other hand, in colorectal cancer HCT116 cells, C6 inhibited the activation of ERK1/2, cyclin-dependent kinase 1, and AKT, down-regulated the protein level of XIAP, and up-regulated pro-apoptotic Bax and caspase-3/7 expression. These alterations are suggested to be involved in the C6-induced suppression of cell cycle/proliferation and initiation of apoptosis in the cancer cells. More importantly, in cancer cells, the treatment of C6 potentiates the anti-cancer effects of DNA-damaging agents. Thus, C6 may be a promising lead for the generation of a novel class of cancer therapeutics. |
format | Online Article Text |
id | pubmed-8998738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89987382022-04-12 A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling Tanuma, Sei-ichi Oyama, Takahiro Okazawa, Miwa Yamazaki, Hiroaki Takao, Koichi Sugita, Yoshiaki Amano, Shigeru Abe, Takehiko Sakagami, Hiroshi Int J Mol Sci Article The current anti-cancer treatments are not enough to eradicate tumors, and therefore, new modalities and strategies are still needed. Most tumors generate an inflammatory tumor microenvironment (TME) and maintain the niche for their development. Because of the critical role of inflammation via high-mobility group box 1 (HMGB1)–receptor for advanced glycation end-products (RAGE) signaling pathway in the TME, a novel compound possessing both anti-cancer and anti-inflammatory activities by suppressing the HMGB1-RAGE axis provides an effective strategy for cancer treatment. A recent work of our group found that some anti-cancer 3-styrylchromones have weak anti-inflammatory activities via the suppression of this axis. In this direction, we searched such anti-cancer molecules possessing potent anti-inflammatory activities and discovered 7-methoxy-3-hydroxy-styrylchromone (C6) having dual suppressive activities. Mechanism-of-action studies revealed that C6 inhibited the increased phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) under the stimulation of HMGB1-RAGE signaling and thereby suppressed cytokine production in macrophage-like RAW264.7 cells. On the other hand, in colorectal cancer HCT116 cells, C6 inhibited the activation of ERK1/2, cyclin-dependent kinase 1, and AKT, down-regulated the protein level of XIAP, and up-regulated pro-apoptotic Bax and caspase-3/7 expression. These alterations are suggested to be involved in the C6-induced suppression of cell cycle/proliferation and initiation of apoptosis in the cancer cells. More importantly, in cancer cells, the treatment of C6 potentiates the anti-cancer effects of DNA-damaging agents. Thus, C6 may be a promising lead for the generation of a novel class of cancer therapeutics. MDPI 2022-03-22 /pmc/articles/PMC8998738/ /pubmed/35408786 http://dx.doi.org/10.3390/ijms23073426 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tanuma, Sei-ichi Oyama, Takahiro Okazawa, Miwa Yamazaki, Hiroaki Takao, Koichi Sugita, Yoshiaki Amano, Shigeru Abe, Takehiko Sakagami, Hiroshi A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling |
title | A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling |
title_full | A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling |
title_fullStr | A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling |
title_full_unstemmed | A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling |
title_short | A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling |
title_sort | dual anti-inflammatory and anti-proliferative 3-styrylchromone derivative synergistically enhances the anti-cancer effects of dna-damaging agents on colon cancer cells by targeting hmgb1-rage-erk1/2 signaling |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998738/ https://www.ncbi.nlm.nih.gov/pubmed/35408786 http://dx.doi.org/10.3390/ijms23073426 |
work_keys_str_mv | AT tanumaseiichi adualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT oyamatakahiro adualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT okazawamiwa adualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT yamazakihiroaki adualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT takaokoichi adualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT sugitayoshiaki adualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT amanoshigeru adualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT abetakehiko adualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT sakagamihiroshi adualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT tanumaseiichi dualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT oyamatakahiro dualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT okazawamiwa dualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT yamazakihiroaki dualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT takaokoichi dualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT sugitayoshiaki dualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT amanoshigeru dualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT abetakehiko dualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling AT sakagamihiroshi dualantiinflammatoryandantiproliferative3styrylchromonederivativesynergisticallyenhancestheanticancereffectsofdnadamagingagentsoncoloncancercellsbytargetinghmgb1rageerk12signaling |